Shares of NuCana plc NCNA skyrocketed 150.8% on Monday after the announcement of encouraging final data from the mid-stage ...

NuCana called the cancellation of the study, which followed a committee recommendation, a ‘disappointing’ and ‘unexpected ...

NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in ...

NuCana's American depositary receipts nearly doubled on Monday after the company reported positive data for its metastatic melanoma treatment. In premarket trading ADRs were up $2.44 to $4.98. However ...

NuCana plc is a clinical-stage biopharmaceutical company dedicated to enhancing cancer treatments through its ProTide technology. This innovative approach transforms conventional chemotherapy agents, ...

As of June 30, 2024, NuCana had cash and cash equivalents of $15.3 million, which is expected to provide a cash runway into Q1 2025. While there were prognostic imbalances favoring the control arm ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Nucana (NCNA – Research Report) today. The company’s ...

Oppenheimer analyst Leland Gershell maintained a Buy rating on Nucana (NCNA – Research Report) today and set a price target of $25.00.

Seven of the 12 patients had a progression-free survival time of over five months. Hugh Griffith, NuCana's Founder and CEO, said, "We are very excited to share these data on NUC-7738 in ...

Hugh Griffith, NuCana's Founder and CEO, said, "We are very excited to share these data on NUC-7738 in combination with pembrolizumab in PD-1 inhibitor refractory and resistant patients with melanoma.

On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 ...